Traub Capital Management’s Biogen BIIB Stock Holding History

Traub Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,910	Closed	-$268K	–	137
2025 Q3	$268K	Hold	1,910	–	–	0.26%	98
2025 Q2	$240K	Buy	+1,910	New	+$238K	0.22%	100

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Traub Capital Management's BIIB Position: Q4 2025 in Review

Traub Capital Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 1,910 shares — an estimated $268K sold.

Traub Capital Management first reported a position in BIIB in Q2 2025 and held it in 2 quarters. The position peaked at $268K in Q3 2025. 997 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Traub Capital Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Traub Capital Management sold 1,910 Biogen shares in Q4 2025, an estimated $268K.
Traub Capital Management first reported a position in Biogen in Q2 2025 and held it in 2 quarters.
Traub Capital Management's Biogen position peaked at $268K in Q3 2025.
997 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Traub Capital Management's 13F filing for Q4 2025, filed 29 Jan 2026.